ArticleNews reportPHN-06152026-11-02 15:54 CT

Musk Predicts “Banger Drugs Coming Out” from Eli Lilly

Source · TIKR.com

TLDR

TIKR reports that Eli Lilly raised its 2026 revenue guidance to $91–92 billion, followed by Elon Musk praising its pipeline without naming a drug. The article highlights retatrutide’s reported trial results and an unresolved FDA classification dispute that could affect its market exclusivity.

01—Key points

01Tirzepatide products Mounjaro and Zepbound accounted for 65% of Lilly’s revenue in the first half of 2026, according to the article.
02TIKR reports that retatrutide produced more than twice Ozempic’s weight loss in a head-to-head type 2 diabetes trial; Lilly plans a first-quarter 2027 filing.
03The article says a court returned part of retatrutide’s classification decision to the FDA, while Lilly’s appeal remains pending.

Why it matters Editorial

The reported classification dispute could determine whether retatrutide receives five or 12 years of market exclusivity, affecting Lilly’s next major peptide product.

Read the original at TIKR.com↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.